ALKS (Alkermes plc.) — AI Stock Analysis & Recommendation

Research of August 5, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate ALKS a BUY. The latest price is $39.73.

The research plan

• Entry: $49.61
• Time horizon: weeks

The current technical and fundamental picture for ALKS is mixed, warranting a cautious approach.

Why

The current technical and fundamental picture for ALKS is mixed, warranting a cautious approach. Catalysts to watch: Positive developments in ALKS's CNS pipeline; Continued revenue growth from key CNS medicines; Favorable shifts in analyst sentiment. Key risks: Significant negative earnings growth and recent negative operating cash flow; High short interest and potential for volatility; Product concentration and R&D risks associated with clinical trials.

What could push ALKS higher

• Positive developments in ALKS's CNS pipeline.
• Continued revenue growth from key CNS medicines.
• Favorable shifts in analyst sentiment.

Key risks for ALKS

• Significant negative earnings growth and recent negative operating cash flow.
• High short interest and potential for volatility.
• Product concentration and R&D risks associated with clinical trials.

What each AI research team found

Fundamental team: Neutral · valuation: fair

ALKS presents a mixed fundamental picture with strong revenue growth and high gross margins countered by significant earnings declines and volatile cash flows. While analyst sentiment is positive, the current valuation appears fair given the profitability concerns and leverage. The stock is trading near its current price, with a target reflecting analyst consensus.

• Strong revenue growth (27% YoY) is offset by significant negative earnings growth (-99.4% YoY), creating a mixed picture of top-line expansion versus profitability challenges.
• High gross margins (87.18%) indicate strong pricing power, but modest operating and net margins suggest high operating expenses or R&D costs.
• While TTM Free Cash Flow is positive ($221.8M), recent quarterly operating cash flow has turned negative (-$20.56M), raising concerns about cash generation sustainability.

Technical team: Neutral

ALKS is exhibiting neutral to slightly bearish signals across multiple technical indicators, trading near resistance with low volume conviction. The confluence of bearish moving average crossovers and indecisive price action suggests a potential short-term pullback towards the $48.00 target, with a stop loss placed just above the immediate resistance.

• The price is trading below key moving averages (MA20 and MA50) with the MA20 crossing below the MA50, suggesting a potential bearish short-to-medium term trend, but is currently consolidating near resistance.
• Volume has been below average, indicating a lack of strong conviction, and a recent volume spike on a down day suggests potential distribution within a sideways range.
• Momentum indicators are mixed to neutral, with RSI around 48, MACD showing a bearish crossover, and Stochastic in the mid-range, suggesting no clear directional bias.

Sentiment team: Neutral

Alkermes presents a balanced sentiment profile, with positive news regarding Q2 revenue beats and pipeline potential offset by concerns about declining net income and insider selling. While social media sentiment is positive, professional analyst views and news coverage lean neutral, indicating a stable but unconvincing outlook. The stock's current valuation and mixed analyst outlook suggest a neutral stance with...

• Alkermes (ALKS) news coverage is largely neutral, with recent Q2 earnings beating revenue estimates and highlighting strong sales growth, while the orexin pipeline is viewed as a future catalyst, though concerns remain about valuation and profitability...
• Alkermes (ALKS) exhibits positive sentiment driven by a strong Q2 earnings beat, revenue growth, and promising pipeline developments, though valuation concerns and potential pipeline setbacks remain factors. (Score: 0.15)
• Alkermes presents a mixed sentiment, with a strong core business and positive pipeline outlook offset by recent declines in net income, analyst EPS estimate downgrades, and insider selling, leading to a neutral overall outlook. (Consensus: Neutral)

Risk team: Medium

Alkermes presents a medium-risk profile due to a combination of elevated short interest, financial leverage concerns, and company-specific risks like product concentration and R&D failures. The potential for significant price volatility, coupled with negative cash flow, warrants a cautious approach and a smaller position size.

• High Short Interest and Potential Volatility: Elevated short interest and days to cover suggest potential for significant price swings due to short squeezes or rapid sell-offs, compounded by moderate realized volatility.
• Financial Leverage and Cash Flow Concerns: Increased debt financing raises concerns about financial distress, especially given negative operating cash flow, making the company sensitive to interest rate changes and missed revenue targets.
• Product Concentration and R&D Risk: Revenue dependence on a few key CNS medicines and the inherent risks of clinical trial failures create significant company-specific vulnerabilities.

ALKS at a glance

Market value	$7.0B
Price / earnings	104.4
Revenue growth (year over year)	10.8%
Profit margin	4.0%
Debt / equity	0.84

TradeFlare's published calls on ALKS

• February 24, 2026: reached target, +5.6%
• May 29, 2026: reached target, +15.3%

Every AI call on ALKS since May 13, 2026, and what happened next (9 calls) →

Research of August 5, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.